European Mobtechs Dominate the Supply Market for Mobility-as-a-Service
7.3.2019 20:12:00 EET | Business Wire | Press release
A new study by PTOLEMUS Consulting Group finds that 12 of the top 17 B2B mobility platform providers in the world have their headquarters in Europe. These software suppliers have diverse backgrounds in road operation or technology but are all helped by a favourable environment and numerous city initiatives in Europe.
Frederic Bruneteau, PTOLEMUS’ Managing Director, stated: “While India just launched a vertically integrated national MaaS scheme, mobtechs are proposing a different model that relies on open software platforms for everybody to use. They are giving mobility operators an alternative to the inevitable dogfights between those who will eat (integrate) and those who will be eaten (integrated). This report sheds light on the specialist players that compete alongside government initiatives and giants such as Google and Uber”.
The Mobility Platform Suppliers handbook is the first to identify and appraise MaaS software suppliers and to clarify a very complex market. It will help cities, Public Transport Operators and mobility service providers choose the optimal model and deliver seamless mobility experiences.
The report maps the MaaS value chain and stakeholders. It also establishes the 6 levels of integration needed to deliver a complete MaaS solution. It includes an assessment of 17 key mobility platform suppliers, detailing their key clients, services, investors and case studies.
The handbook unpacks the MaaS ecosystem, stakeholders and architecture, covering:
- The necessary building blocks for a complete mobility platform
- The levels of MaaS integration
- The main players in each part of the MaaS value chain
- The top mobility platform providers
The study features:
- 150 pages of analysis of the complex ecosystem powering mobility-as-a-service,
- 17 MaaS platform suppliers assessed
- High level architecture of shared mobility platforms
- An independent ranking of the top technology providers in the MaaS market.
Download the abstract of the study here.
To discuss these questions directly with the authors, contact us at mobtech@ptolemus.com.
Suppliers analysed:
9 Transport Platform Providers:
- Bestmile
- INVERS
- Ecomobix
- Launch Mobility
- Omoove (Octo Telematics)
- Padam
- Ridecell
- Shotl
- Vulog
8 Mobility Platform Providers:
- A-to-Be (Brisa)
- Cubic
- Fluidtime (Kapsch)
- Moovel / Reach Now (BMW and Daimler)
- Moovit
- Optimile
- Siemens
- SkedGo
About PTOLEMUS Consulting Group
PTOLEMUS is the first strategy consulting & research firm entirely focused on connected & autonomous mobility. It assists leading public organisations, technology players, automotive OEMs, insurers and mobility service providers in defining & deploying their mobility strategies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005576/en/
Contact information
Annie Reddaway, +447912571379, areddaway@ptolemus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom